Gaining greater insight into the patient journey from diagnosis through treatment is a priority for drug developers as they seek to produce more effective drugs. Using non-small cell lung cancer (NSCLC) as an example, PurpleLab and Genentech will explore how to leverage real world data (RWD) to eliminate blind spots in the patient journey — informing every phase of a drug’s lifecycle, from clinical development to market access.
The webinar will include Purple Lab executives Russ Cobb, chief marketing officer and the webinar moderator, and Steve Emrick, senior vice president of clinical informatics solutions and health nexus. Also taking part in the webinar is Dr. Ben Freiberg, Principal Informatics Systems Lead with Genentech’s gCS Computational Catalysts. Genentech is owned by Roche.
Among the talking points the webinar will cover are:
- How can RWD be leveraged by pharma companies for the NSCLC patient journey?
- What does the “typical” patient journey for NSCLC look like?
- Mapping the nuanced parts of a patient’s journey
- The value of leveraging Social Determinants of Health data
- Addressing socioeconomic barriers that may hinder clinical trial participation
- Using RWD to improve clinical trial recruitment, clinical endpoints, and inform market access strategies
To register for the webinar sponsored by PurpleLab, Eliminating Blind Spots in the Patient Journey, scheduled for 1-2 pm ET on May 22, please fill out the form below:
